Noname Launches from Stealth to Eliminate API Security Chaos for Enterprises
15.12.2020 16:00:00 EET | Business Wire | Press release
Noname Security, the enterprise API security company, launched from stealth today with $25 million in funding from Lightspeed, Insight Partners and Cyberstarts. Noname is the only holistic security platform that lets enterprises see and secure managed and unmanaged APIs exposed by the organization, consumed by the organization or used internally, thereby eliminating the API security blind spots that exist in most businesses today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005410/en/
Pictured (left to right): Noname Security Co-founders Oz Golan and Shay Levi. (Photo: Business Wire)
Digital transformation encourages companies to leverage APIs extensively to grow business and promote innovation. However, many have an underdeveloped API security strategy, which creates a major attack surface. Gartner has stated that "by 2022, API abuses will move from an infrequent to the most-frequent attack vector, resulting in data breaches for enterprise web applications."(*)
Noname provides an agentless security platform that gives enterprises a complete view into the activity and threats in their environment. Frictionless to deploy, Noname integrates with existing IT infrastructure and gives businesses visibility, security, and control over any API, whether on or off the corporate API gateways. With Noname, enterprises are able to gain the productivity benefits of using APIs without sacrificing security.
"Application security has a huge blind spot," said Oz Golan, CEO and co-founder of Noname. "A leaky API on T-Mobile’s website exposed customer data. The US Postal Service API vulnerability exposed personal information of 60 million users of its online service. The fact you cannot place agents on every application server, and you cannot trust network architecture to funnel all APIs through a single gateway, means we need a new approach. We built Noname to give enterprises complete visibility into all APIs in their environment without requiring an agent or relying on API gateways. We can stop APIs from compromising corporate assets, regardless of whether those APIs are managed by IT or not."
"Noname's holistic solution to API security is spot on. The breadth and depth of insights provided while being so easy to deploy is magic," said Joseph Tso, a leading banking CISO.
Founded in 2020, and headquartered in Palo Alto, California, with an office in Tel Aviv, the Noname team is composed of top engineering talent from Israel and experienced Silicon Valley technology leaders. Noname CEO and co-founder Oz Golan was Director of Engineering at NSO. He served with co-founder and CTO Shay Levi in the selective Unit 8200 of the Israeli Defense Forces, whose alumni also founded Check Point, Waze (acquired by Google) and Palo Alto Networks.
Gili Raanan, Cyberstarts founder, was the first to partner with Noname, while Guru Chahal, Partner at Lightspeed Venture Partners, and Thomas Krane, Principal at Insight Partners, joined to close the Series A round.
"The exponential growth of APIs introduces risk that most enterprises are not prepared to handle," said Gili Raanan of Cyberstarts. "Oz and Shay's strong vision combined with their decision to blend top Israeli engineering talent with sales and marketing executives from Cylance, Armis and NSO set them up for success."
"Noname presents a big opportunity to help enterprises navigate the uncharted territory of APIs in their environment," said Guru Chahal of Lightspeed Venture Partners. "We were impressed with how the team has really listened to their customers to deliver what businesses need. Customers especially liked the on-click frictionless deployment for API discovery and stopping unauthorized access to their applications."
"Our investment in Noname represents Insight’s commitment to partnering with the next generation of Israeli software ScaleUps," said Thomas Krane, Principal at Insight Partners. "Noname’s pure-play API security platform delivers on the long-awaited hope for true runtime application security and will enable enterprises to continue their digital transformation without sacrificing security. We are thrilled to partner with Oz, Shay, and the rest of the team to bring the Noname product to the global enterprise community."
To learn more about Noname visit: www.nonamesecurity.com
(*) Gartner, API Security: What You Need to Do to Protect Your APIs, Mark O’Neill, Dionisio Zumerle, et al., 28 August 2019.
About Noname Security
Noname Security eliminates API security blind spots and protects enterprises from data leakage, authorization issues, abuse, misuse and data corruption with no agents and no network modifications. Fortune 500 companies trust Noname's holistic API security platform to see and secure their APIs. Noname is a privately held company headquartered in Palo Alto, California, with an office in Tel Aviv. www.nonamesecurity.com
About Lightspeed Venture Partners
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer, and Health sectors. Over the past two decades, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 400 companies globally, including Snap, Nest, Nutanix, AppDynamics, MuleSoft, OYO, Guardant, StitchFix, and GrubHub. Lightspeed and its affiliates currently manage $10.5B across the global Lightspeed platform, with investment professionals and advisors in Silicon Valley, Israel, India, China, Southeast Asia and Europe. www.lsvp.com
About Insight Partners
Insight Partners is a leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies that are driving transformative change in their industries. Founded in 1995, Insight Partners has invested in more than 400 companies worldwide and has raised through a series of funds more than $30 billion in capital commitments. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with practical, hands-on software expertise to foster long-term success. Across its people and its portfolio, Insight encourages a culture around a belief that ScaleUp companies and growth create opportunity for all. www.insightpartners.com
About Cyberstarts
Cyberstarts is a venture capital firm focused on cybersecurity and is backed by successful cybersecurity entrepreneurs. Cyberstarts is a leading platform for amazing teams of entrepreneurs solving the next big pain points in the cybersecurity world. Cyberstarts founder, Gili Raanan, was the first investor in cybersecurity-focused companies like Armis, Adallom, Axis and Fireblocks. www.cyberstarts.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005410/en/
Contact information
Noname Security
Shay Levi | shay@nonamesecurity.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom